For the quarter ending 2025-09-30, ASRT had -$8,586K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 11,445 | -29,893 |
| Depreciation and amortization | 5,630 | 18,536 |
| Amortization of debt issuance costs | 120 | 233 |
| Accretion of interest income from short-term investments | -8 | -36 |
| Loss on assertio therapeutics divestiture | 0 | -8,174 |
| Impairment of intangible assets | 1,700 | - |
| Recurring fair value measurements of assets and liabilities | 302 | -34 |
| Provisions for inventory | 522 | 2,675 |
| Stock-based compensation | 1,067 | 2,290 |
| Accounts receivable | 80,217 | 6,970 |
| Inventories | -7,595 | -2,753 |
| Prepaid and other assets | -14,017 | 7,912 |
| Accounts payable and other accrued liabilities | -10,351 | 7,014 |
| Accrued rebates, returns and discounts | 44,649 | 9,583 |
| Interest payable | -650 | - |
| Net cash provided by operating activities | -4,767 | 6,553 |
| Assertio therapeutics divestiture | 0 | 8,174 |
| Proceeds from maturities of short-term investments | 27,660 | 57,572 |
| Purchases of short-term investments | 31,472 | 59,273 |
| Net cash used in investing activities | -3,812 | -9,875 |
| Payments related to the vesting and settlement of equity awards, net | 7 | 180 |
| Net cash used in financing activities | -7 | -180 |
| Net decrease in cash and cash equivalents | -8,586 | -3,502 |
| Cash and cash equivalents at beginning of period | 50,588 | - |
| Cash and cash equivalents at end of period | 38,500 | - |
Assertio Holdings, Inc. (ASRT)
Assertio Holdings, Inc. (ASRT)